HealthTree Research: Bispecific Antibody Study
What are real-world experiences of myeloma patients with bispecific antibodies—such as Teclistamab (Tecvayli), Talquetamab (Talvey), and Elranatamab (Elrexfio)?
Go directly to survey
STUDY IMPACT
The multiple myeloma medical community is now able to provide bispecific antibody therapy to patients. The study gathers information about various aspects of the patient experience with bispecific antibodies, ranging from initial awareness to quality of life after at least four months of treatment. Your experience can help inform:
- How patients make treatment decisions
- Side effects and patient outcomes
- Step-up dosing challenges
- Differences in care between academic vs. community centers
- Caregiver burden and financial impact
- Quality of life during and after treatment
Because there are now three FDA approved bispecific antibodies with more coming in clinical development, this is critical information doctors need to know to correctly prescribe this therapy to myeloma patients. This extensive study will help identify the type of patient best helped by this class of treatment and the optimal sequencing of bispecific antibodies in myeloma care.
WHO CAN JOIN
Multiple myeloma patients after at least 4 months of having received a bispecific antibody (as an FDA-approved treatment or as part of a clinical trial).
HOW TO PARTICIPATE
- Sign in or create a free Cure Hub account
- Connect your medical records (takes less than 5 minutes)
- Complete 8 surveys over time (each survey takes 10–25 minutes)
Join the Study Today
RESEARCH PARTNERS
ABOUT HEALTHTREE CURE HUB
